… Besides imatinib, dasatinib and nilotinib have expanded therapeutic options for pediatric
CML treatment. Ongoing investigations into bosutinib and ponatinib show promise as potential …

… Methods: We checked DDIs of 100 drugs with six BCR-ABL TKIs—dasatinib, imatinib,
nilotinib, ponatinib, bosutinib, and asciminib—in two subscription-based databases (UpToDate …

… Nilotinib and dasatinib showed a tendency towards a higher risk of pPKI-DI compared to
imatinib. Despite the fact that some PKI-DIs were potentially clinically relevant, we did not find …

… 3.6 μM with nilotinib to over 100 μM with dasatinib, lapatinib, … Moreover, in this study, we
find that nilotinib was the TKI with … that imatinib and nilotinib were potent Pgp inhibitors with IC …

… of ceritinib, bosutinib, dasatinib, nilotinib and pazopanib are … , erlotinib, gefitinib, imatinib,
lapatinib, nilotinib, nintedanib, … Because tyrosine kinase inhibitors are largely eliminated by …

… with dasatinib, nilotinib and ponatinib compared with imatinib, such an … Despite the use of
nilotinib has been associated with … Drug interactions between TKIs and other prescribed drugs …

… due to the advent of novel tyrosine kinase inhibitors (TKI) and trials … , we have imatinib as first
generation TKI; nilotinib, dasatinib, … Drug interactions of dasatinib have been summarized in …

… the actual clinical evidence and drug-drug interaction, and provided countermeasures to QT
… such as nilotinib (9) and dasatinib (10), exhibited the ability to overcome imatinib resistance …

… This review aims to elucidate the drug profiles of TKIs (imatinib, dasatinib, nilotinib, bosutinib,
ponatinib, and asciminib) related to CML, to understand their pharmacological differences …

… The introduction of tyrosine kinase inhibitors (TKIs) has … , baseline comorbidities, possible
drug interactions, adverse events … used in the real-life in CP-CML patients after imatinib failure …